PDF(Pubmed)
Abstract：
BACKGROUND: Oral lichen planus (OLP) is a chronic mucocutaneous disease affecting the general population, with its exact etiology remaining unknown. This condition is characterized by T-cell mediated autoimmunity wherein auto-cytotoxic CD8+ T cells precipitate basal cell apoptosis in the oral epithelium. Conventionally, corticosteroids have been the mainstay of treatment for OLP, necessitating the exploration of alternatives to mitigate long-term corticosteroid-related adverse effects. Amlexanox, a topical anti-inflammatory agent, impedes the synthesis and release of histamine, TNF-alpha, and leukotrienes from mast cells, neutrophils, and mononuclear cells, conceivably implicated in OLP pathogenesis.
OBJECTIVE: The study aims to evaluate and compare the clinical efficacy of topical amlexanox and triamcinolone acetonide in the treatment of OLP.
OBJECTIVE: The objectives of this study are (i) to evaluate the lesion size following the topical application of 5% amlexanox paste in the treatment of OLP, (ii) to evaluate the burning sensation of the patient based on the VAS score, and (iii) to compare and evaluate the clinical efficacy of 5% amlexanox with 0.1% triamcinolone acetonide in the treatment of OLP.
METHODS: Forty patients clinically and histopathologically diagnosed with symptomatic OLP were randomly assigned into two groups, each comprising 20 patients. Group A was prescribed topical 5% amlexanox, while Group B received topical 0.1% triamcinolone acetonide with instructions to apply the drug at the site of the lesion intraorally thrice a day after food. The clinical improvement was evaluated using the Thongprasom scale, and the burning sensation was assessed using the visual analog scale (VAS) score weekly over four weeks.
RESULTS: The study showed that there was a statistically significant reduction in the VAS score and size of lesion with each drug individually (p=0.000). There was a statistically significant difference in the mean values of VAS scores and size of the lesion between the first visit and fourth week, indicating a gradual reduction of the burning sensation and size of the lesion in both Group A and Group B, respectively. When both the groups were compared, there was no significant difference (p>0.05) in the reduction of burning sensation between Group A and Group B, indicating that amlexanox was as effective as triamcinolone in reducing the VAS score. However in terms of reduction of lesion size during the second week (p=0.022) and the third week (p=0.013), a statistically significant value was seen with a greater reduction in the size of the lesion in Group B compared to Group A.
CONCLUSIONS: Given its anti-inflammatory properties and lower incidence of adverse effects relative to corticosteroids, amlexanox acts as a promising first-line therapeutic option for OLP. In cases of inadequate response, adjunctive therapies can be considered.
OBJECTIVE: The study aims to evaluate and compare the clinical efficacy of topical amlexanox and triamcinolone acetonide in the treatment of OLP.
OBJECTIVE: The objectives of this study are (i) to evaluate the lesion size following the topical application of 5% amlexanox paste in the treatment of OLP, (ii) to evaluate the burning sensation of the patient based on the VAS score, and (iii) to compare and evaluate the clinical efficacy of 5% amlexanox with 0.1% triamcinolone acetonide in the treatment of OLP.
METHODS: Forty patients clinically and histopathologically diagnosed with symptomatic OLP were randomly assigned into two groups, each comprising 20 patients. Group A was prescribed topical 5% amlexanox, while Group B received topical 0.1% triamcinolone acetonide with instructions to apply the drug at the site of the lesion intraorally thrice a day after food. The clinical improvement was evaluated using the Thongprasom scale, and the burning sensation was assessed using the visual analog scale (VAS) score weekly over four weeks.
RESULTS: The study showed that there was a statistically significant reduction in the VAS score and size of lesion with each drug individually (p=0.000). There was a statistically significant difference in the mean values of VAS scores and size of the lesion between the first visit and fourth week, indicating a gradual reduction of the burning sensation and size of the lesion in both Group A and Group B, respectively. When both the groups were compared, there was no significant difference (p>0.05) in the reduction of burning sensation between Group A and Group B, indicating that amlexanox was as effective as triamcinolone in reducing the VAS score. However in terms of reduction of lesion size during the second week (p=0.022) and the third week (p=0.013), a statistically significant value was seen with a greater reduction in the size of the lesion in Group B compared to Group A.
CONCLUSIONS: Given its anti-inflammatory properties and lower incidence of adverse effects relative to corticosteroids, amlexanox acts as a promising first-line therapeutic option for OLP. In cases of inadequate response, adjunctive therapies can be considered.
摘要：
背景：口腔扁平苔藓（OLP）是一种影响普通人群的慢性皮肤粘膜疾病，其确切病因尚不清楚。该病症的特征在于T细胞介导的自身免疫,其中自身细胞毒性CD8+T细胞在口腔上皮中沉淀基底细胞凋亡。传统上,皮质类固醇一直是OLP的主要治疗手段,有必要探索替代品以减轻长期皮质类固醇相关的不良反应。Amlexanox,一种局部抗炎药，阻碍组胺的合成和释放，TNF-α,和肥大细胞的白三烯，中性粒细胞，和单核细胞，可能与OLP发病机制有关。
目的：本研究旨在评估和比较局部使用氨来诺司和曲安奈德治疗OLP的临床疗效。
目的：本研究的目的是（i）评估局部应用5％amlexanox糊剂治疗OLP后的病变大小，（ii）根据VAS评分评估患者的烧灼感，和（iii）比较和评估5％氨来酸与0.1％曲安奈德治疗OLP的临床疗效。
方法：将40例临床和组织病理学诊断为症状性OLP的患者随机分为两组，每人包括20名患者。A组局部用药5%amlexanox,而B组接受0.1%曲安奈德外用，并说明在进食后一天三次口服在病变部位施用药物。使用Thongprasom量表评估临床改善情况，并在四周内每周使用视觉模拟量表（VAS）评分评估灼烧感。
结果：研究表明，每种药物的VAS评分和病变大小均有统计学上的显着降低（p=0.000）。第一次就诊和第4周的VAS评分平均值和病灶大小差异有统计学意义，表明A组和B组的烧灼感和病变大小逐渐减少，分别。当两组比较时，A组与B组的烧灼感降低差异无统计学意义(p>0.05),这表明amlexanox在降低VAS评分方面与曲安奈德一样有效.然而，就第二周（p=0.022）和第三周（p=0.013）病变大小的减少而言，与A组相比，B组的病变大小减少更大，具有统计学意义。
结论：鉴于其抗炎特性和相对于皮质类固醇的不良反应发生率较低，amlexanox是OLP的有前途的一线治疗选择。在反应不足的情况下，可以考虑辅助治疗。
目的：本研究旨在评估和比较局部使用氨来诺司和曲安奈德治疗OLP的临床疗效。
目的：本研究的目的是（i）评估局部应用5％amlexanox糊剂治疗OLP后的病变大小，（ii）根据VAS评分评估患者的烧灼感，和（iii）比较和评估5％氨来酸与0.1％曲安奈德治疗OLP的临床疗效。
方法：将40例临床和组织病理学诊断为症状性OLP的患者随机分为两组，每人包括20名患者。A组局部用药5%amlexanox,而B组接受0.1%曲安奈德外用，并说明在进食后一天三次口服在病变部位施用药物。使用Thongprasom量表评估临床改善情况，并在四周内每周使用视觉模拟量表（VAS）评分评估灼烧感。
结果：研究表明，每种药物的VAS评分和病变大小均有统计学上的显着降低（p=0.000）。第一次就诊和第4周的VAS评分平均值和病灶大小差异有统计学意义，表明A组和B组的烧灼感和病变大小逐渐减少，分别。当两组比较时，A组与B组的烧灼感降低差异无统计学意义(p>0.05),这表明amlexanox在降低VAS评分方面与曲安奈德一样有效.然而，就第二周（p=0.022）和第三周（p=0.013）病变大小的减少而言，与A组相比，B组的病变大小减少更大，具有统计学意义。
结论：鉴于其抗炎特性和相对于皮质类固醇的不良反应发生率较低，amlexanox是OLP的有前途的一线治疗选择。在反应不足的情况下，可以考虑辅助治疗。
